

论著

小细胞肺癌合并低钠血症的临床特点及预后分析

马芳, 刘先领, 胡春宏, 黄明

中南大学湘雅二医院肿瘤科, 长沙 410011

摘要:

目的: 探讨小细胞肺癌合并低钠血症患者的临床特点及预后。方法: 对中南大学湘雅二医院肿瘤科2000年1月至2007年12月间收治的158例小细胞肺癌患者进行回顾性分析。结果: 小细胞肺癌患者中合并低钠血症者67例, 占42.4%, 其中位生存期为7.6个月; 血钠正常组中位生存期为14.1个月, 两者比较差异有统计学意义($P<0.001$)。治疗后血钠仍低组中位生存期为6.2个月, 治疗后血钠恢复正常组中位生存期为10.3个月, 两者比较差异有统计学意义($P=0.044$)。结论: 小细胞肺癌易合并发生低钠血症; 合并低钠血症者较未合并者, 其中位生存期明显下降; 治疗后血钠未恢复正常者较恢复者预后更差, 故应及早诊断和治疗。

关键词: 小细胞肺癌; 低钠血症; 临床特点; 预后

Clinical features and prognosis analysis of small cell lung cancer complicated with hyponatremia

MA Fang, LIU Xianling, HU Chunhong, HUANG Ming

Department of Medical Oncology, Second Xiangya Hospital, Central South University, Changsha 410011, China

Abstract:

Objective To evaluate the clinical features and prognosis of small cell lung cancer (SCLC) complicated with hyponatremia. Methods The clinical data of 158 patients with SCLC of the Second Xiangya Hospital from January 2000 to December 2007 were studied retrospectively. Results The incidence rate of hyponatremia in SCLC was 42.4%(67/158). The median survival time was 7.6 months in patients with subnormal serum sodium, and 14.1 months in patients with normal values. There was significantly different between 2 groups ($P<0.001$). The patients who did not fully regain normal values of serum sodium, had poorer survival (6.2 months) compared with the patients with normal serum sodium (10.3 months, $P=0.044$). Conclusion The incidence rate of hyponatremia in SCLC is high. The prognosis of SCLC with hyponatremia is very poor, especially in those who can not regain normal values of serum sodium after the treatment. So diagnosis and treatment at early stage are very important.

Keywords: small cell lung cancer; hyponatremia; clinical features; prognosis

收稿日期 2010-10-13 修回日期 网络版发布日期

DOI: 10.3969/j.issn.1672-7347.2011.

基金项目:

湖南省科技厅计划资助项目(2009WK3057)

通讯作者: 刘先领

作者简介: 马芳, 博士研究生, 主治医师, 主要从事恶性肿瘤综合治疗及其机制的研究。

作者Email: liuxianling3180@yahoo.com.cn

参考文献:

[1] Vanhees S L, Paridaens R, Vansteenkiste J F. Syndrome of inappropriate antidiuretic hormone associated with chemotherapy induced tumour lysis in small cell lung cancer: case report and literature review [J]. Ann Oncol, 2000, 11(8):1061-1065.

[2] Raftopoulos H. Diagnosis and management of hyponatremia in cancer patients [J]. Support Care Cancer, 2007, 15(12):1341-1347.

[3] 吴在德, 吴肇汉. 外科学 [M]. 6版. 北京: 人民卫生出版社, 2006: 25-26. WU Zaide, WU Zhaohan. Surgery [M]. 6th ed. Beijing: People's Medical Publishing House, 2006: 25-26.

扩展功能

本文信息

Supporting info

PDF(887KB)

[HTML全文]

参考文献[PDF]

参考文献

服务与反馈

把本文推荐给朋友

加入我的书架

加入引用管理器

引用本文

Email Alert

文章反馈

浏览反馈信息

本文关键词相关文章

小细胞肺癌; 低钠血症; 临床特点; 预后

本文作者相关文章

PubMed

[4] Radulescu D, Pripon S, Bunea D, et al. Endocrine paraneoplastic syndromes in small cell lung carcinoma. Two case reports [J]. J BUON, 2007, 12(3):411-414.

[5] Hansen O, Sørensen P, Hansen K H. The occurrence of hyponatremia in SCLC and the influence on prognosis: a retrospective study of 453 patients treated in a single institution in a 10-year period [J]. Lung Cancer, 2010, 68(1):111-114.

[6] 马文静, 李平. 低钠血症与肿瘤 [J]. 临床肺科杂志, 2009, 14(2):217-218.

MA Wenjing, LI Ping. Hyponatremia and tumor [J]. Journal of Clinical Pulmonary Medicine, 2009, 14

(2):217-218. [7] Oruckaptan H H, Ozisik P, Akalan N. Prolonged cerebral salt wasting syndrome associated with the intraventricular dissemination of brain tumors. Report of two cases and review of the literature [J]. Pediatr Neurosurg, 2000, 33(1):16-20.

[8] Iyer A V, Krasnow S H, Dufour D R, et al. Sodium wasting nephropathy caused by cisplatin in a patient with small cell lung cancer [J]. Clin Lung Cancer, 2003, 5(3):187-189.

[9] Oiso Y. Hyponatremia: how to approach this confusing abnormality [J]. Intern Med, 1998, 37(11):907-908.

[10] Kim Y H, Goto K, Yoh K, et al. Performance status and sensitivity to first-line chemotherapy are significant prognostic factors in patients with recurrent small cell lung cancer receiving second-line chemotherapy [J]. Cancer, 2008, 113(9):2518-2523.

[11] 邵亚娟, 王颖轶, 孟长婷, 等. 小细胞肺癌77例治疗及预后分析 [J]. 中国医学科学院学报, 2010, 32(4):394-397.

SHAO Yajuan, WANG Yingyi, MENG Changting, et al. Treatment and Prognosis of 77 Cases of Small Cell Lung Cancer [J]. Acta Academiae Medicinae Sinicae, 2010, 32(4):394-397.

[12] Bremnes R M, Sundstrom S, Aasebo U, et al. The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up [J]. Lung Cancer, 2003, 39(3):303-313.

[13] Rawson N S, Peto J. An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research [J]. Br J Cancer, 1990, 61(4):597-604.

[14] 成远, 龚新雷, 李嵘, 等. 紫杉醇为主的方案治疗复发性小细胞肺癌的临床观察 [J]. 中国现代医学杂志, 2009, 19(13):2056-2062.

CHENG Yuan, GONG Xinlei, LI Rong, et al. Clinical observation of paclitaxol based chemotherapy on recurrent small cell lung cancer [J]. China Journal of Modern Medicine, 2009, 19(13): 2056-2062.

本刊中的类似文章